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Peroxisome proliferator-activated receptors (PPARs)
are activated by an array of polyunsaturated fatty acid
derivatives, oxidized fatty acids, and phospholipids
and are proposed to be important modulators of im-
mune and inflammatory responses. Recently, we
showed that activation of PPAR- alters the matura-
tion process of dendritic cells (DCs), the most potent
antigen-presenting cells. In the present report, we
investigated the possibility that, by targeting DCs,
PPAR- activation may be involved in the regulation
of the pulmonary immune response to allergens. Us-
ing a model of sensitization, based on the intratra-
cheal transfer of ovalbumin (OVA)-pulsed DCs, we
show that rosiglitazone, a selective PPAR- agonist,
reduces the proliferation of Ag-specific T cells in the
draining mediastinal lymph nodes but, surprisingly
enough, dramatically increases the production of the
immunoregulatory cytokine interleukin (IL)-10 by T
cells, as compared to control mice sensitized with
OVA-pulsed DCs. After aerosol challenge, the recruit-
ment of eosinophils in the bronchoalveolar lavage
fluids was strongly reduced compared to control
mice. Finally, T cells from the mediastinal lymph
nodes produced higher amounts of IL-10 and interfer-
on-. Inhibition of IL-10 activity with anti-IL-10R an-
tibodies partly restored the inflammation. The speci-
ficity of the phenomenon was confirmed by treating
OVA-pulsed DCs with ciglitazone, another PPAR- ag-
onist, and by using GW9662, a PPAR- antagonist. Our
data suggest that PPAR- activation prevents induc-
tion of Th2-dependent eosinophilic airway inflamma-
tion and might contribute to immune homeostasis in
the lung. (Am J Pathol 2004, 164:263–271)
Dendritic cells (DCs) are powerful antigen-presenting
cells with a unique capacity to stimulate naı¨ve T cells.1 In
the airways, immature lung DCs are ideally placed to
sample inhaled antigens.2 After they acquire antigens in
the periphery, DCs migrate to the draining lymph nodes
(LNs) where they localize in the T cell-rich area and
initiate immune responses. However, some evidence also
suggests that tissue-resident DCs take up tissue anti-
gens, migrate to the afferent LNs even in the absence of
inflammatory conditions,3 and contribute to the mainte-
nance of tolerance.4,5
The signals that control DC migration from the periph-
ery to the LNs are not fully understood. During inflamma-
tion, it is known that tumor necrosis factor- and/or inter-
leukin (IL)-1 provoke the departure of DCs from the
periphery to the draining LNs by affecting the expression
of adhesion molecules and chemokine receptors (partic-
ularly CCR7), by increasing the synthesis of metallopro-
teinases and by stimulating actin-dependent move-
ments.6–10 In addition to inflammatory cytokines and
chemokines, other factors such as fatty acid derivatives
also play a critical role in DC migration. For instance,
LTC4 and PGE2, two major lipoxygenase and cyclooxy-
genase products of arachidonic acid, have been shown
to promote the chemokine-driven DC migration.11,12 On the
other hand, by activating the D prostanoid receptor 1 (DP1),
PGD2 has an opposite action by preventing the departure of
DCs from the skin and from the lung to the draining
LNs.13,14 PGD2 is further metabolized into the cyclopen-
tenone prostaglandin 15-deoxy-(12,14)-prostaglandin-J2
(15d-PGJ2), a peroxisome proliferator-activated receptor
(PPAR)- agonist. PPARs are nuclear eicosanoid receptor
transcription factors that regulate adipocyte differentiation
and metabolism.15 Three PPAR isoforms (, , and ) have
been identified. PPAR- is expressed in adipocytes, in the
vascular wall,16 and in cells of the immune system such as
monocytes/macrophages,17,18 B and T cells,19,20 and
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DCs.21,22 Moreover, it has been proposed that PPAR-may
possess anti-inflammatory properties.23–25 We have re-
cently shown that PPAR-, a fatty acid-activated nuclear
receptor, inhibits the tumor necrosis factor--induced mi-
gration of epidermal Langerhans cells and reduces the
spontaneous migration of lung DCs.13,26 These findings
have encouraged different laboratories to investigate the
role of PPAR- as therapeutic targets for immune-mediated
diseases. PPAR- agonists such as the thiazolidinedione
class of anti-diabetic drugs have been shown to suppress
experimental 2,4,6-trinitro-benzene sulfonic acid (TNBS) in-
duced colitis and experimental allergic encephalitis.27–29
Very recently, an effect of PPAR- agonists on lung allergic
responses has also been observed.30,31
In this study, using a model of sensitization based on
the intratracheal transfer of ovalbumin (OVA)-pulsed
DCs,32,33 we show that the PPAR- agonist rosiglitazone
(RSG) inhibits the migration of antigen-loaded DCs in the
mediastinal lymph nodes (MLNs) and reduces, in a quan-
titative and qualitative manner, the T-cell response in the
MLNs. After challenge, a marked shift in the immune
response [increased interferon (IFN)- and IL-10] was
observed in the MLNs and was accompanied by a sig-
nificant decrease in airway eosinophilia. These data sug-
gest that activation of PPAR- in lung DCs might be
important in the regulation of airway inflammatory dis-
eases such as asthma.
Materials and Methods
Reagents and Antibodies
Reagents
OVA was from Worthington Biochemical Corp (Lake-
wood, NJ). At the dose we used in our experiments, the
endotoxin level of OVA measured by a limulus-amebo-
cyte lysate assay (Biowhittaker, Verviers, Belgium) was
0.001 g. RSG was kindly provided by Dr. A. Bril (Glaxo
Smithkline, Rennes). The PPAR- agonist ciglitazone and
the PPAR- antagonist GW9662 were from Cayman (Ann
Arbor, MI). Carboxyfluorescein diacetate succinimidyl
ester (CFSE) was from Molecular Probes (Eugene, OR).
The fluorescein isothiocyanate (FITC)-conjugated anti-I-
Ad/I-Ed (M5/114.5.2), Cy-chrome-labeled anti-CD3
(145.2C11), and anti-CD45R (RA3-6B2), and APC-la-
beled anti-CD4 (RM4-5) and anti-CD11c (HL3) were all
from Pharmingen (Heidelberg, Germany). The phyco-
erythrin (PE)-conjugated anti-CCR3 and KJ1-26 (clono-
typic OVA-TCR) were from R&D (Abingdon, UK) and
Caltag Laboratories (Burlingame, CA). The polyclonal
rabbit anti-PPAR- was from Calbiochem (San Diego,
CA) and the secondary FITC-labeled goat anti-rabbit was
from Nordic Laboratories (Aalborg, Denmark). The
CCL19-Fc was a gift from J. Cyster (University of San
Francisco, San Francisco, CA) and the secondary FITC-
labeled anti-human IgG Fab fragments were from Jack-
son Immunoresearch Laboratories (West Grove, PA).
Mice
BALB/c mice (6 to 8 weeks old) were purchased from
Harlan (Zeist, The Netherlands). OVA-TCR transgenic
mice (DO11.10) on a BALB/c background were bred at
the Erasmus University (Rotterdam, The Netherlands).34
All experiments were performed according to institutional
guidelines of the animal ethics committee at Erasmus
Medical Center.
Generation and Antigen Pulsing of Bone
Marrow DCs
DCs were prepared as previously described.35 Briefly,
bone marrow was flushed with RPMI 1640 (Invitrogen,
Paisley, UK) from femurs and tibiae of BALB/c mice. Cells
were washed, enumerated, and plated in bacteriological
100-mm-diameter Petri dishes. Cell-culture medium
(TCM) was RPMI 1640 supplemented with gentamicin (60
g/ml), 2-mercaptoethanol (5 105 mol/L) and 5% fetal
calf serum (Biocell Laboratories). At day 0 of the culture,
the cells were seeded at a concentration of 2  106/dish in
medium containing rm GM-CSF (200 IU/ml) (kindly pro-
vided by K. Thielemans, University of Brussels, Belgium). At
day 3, TCM containing 200 IU/ml rm GM-CSF was added.
At days 6 and 8, half of the medium was collected, centri-
fuged, and the pellet was resuspended in TCM containing
200 IU/ml of recombinant murine GM-CSF.
At day 9 of the culture, DCs were pulsed overnight with
100 g/ml of OVA containing the vehicle (dimethyl sul-
foxide) in which RSG was resuspended (OVA-DCs), or
with medium alone as a control. To stimulate PPAR-,
some plates were also treated with 10 mol/L of RSG
(RSG/OVA-DCs) or 10 mol/L of ciglitazone added 30
minutes before addition of OVA. To confirm the specificity
of the phenomenon, in some experiments, we also pre-
treated DCs with 10 mol/L of the PPAR- antagonist
GW9662 for 30 minutes before the addition of RSG. After
antigen pulsing overnight, nonadherent DCs were col-
lected, washed to remove free OVA or RSG, and resus-
pended in phosphate-buffered saline (PBS) at a concen-
tration of 12.5 106 cells/ml. The viability of the DCs after
treatment with the agonists or with the antagonist was
99% as assessed by trypan blue exclusion.
The phenotype of DCs was determined by staining for
30 minutes with CD11c-APC, MHCII-FITC, in combination
with CD40-PE, CD80-PE, and CD86-PE dissolved in PBS
containing 0.5% bovine serum albumin and 0.01% so-
dium azide. To detect CCR7 expression, DCs were first
stained with CCL19-Fc for 30 minutes, washed, and in-
cubated for another 30 minutes with anti-human IgG.
DCs were washed and analyzed by flow cytometry on a
FACScalibur (BD).
Intratracheal Injection of DCs
Mice were anesthetized with avertin (2% v/v in PBS) and
80 l of the cell suspension (1  106 DCs) was instilled
through the opening vocal cords.
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Migration of DCs
At day 10 of the culture, unpulsed DCs and OVA-pulsed
DCs treated or not with RSG were collected, washed, and
labeled with CFSE as previously described.33 One million
DCs were instilled into the trachea of naı¨ve BALB/c mice.
Twenty-four hours later, MLNs were collected and
minced using scissors. The LNs were then incubated for
1 hour at 37°C in RPMI 1640 containing 5% fetal calf
serum, 1 mg/ml collagenase type 2 (Worthington), and
0.02 mg/ml DNase I (Sigma, Zwijndrecht, The Nether-
lands), according to a modified protocol.36 LN cells were
resuspended in PBS containing 10 mmol/L of ethyl-
enediaminetetraacetic acid and centrifuged. CFSE DCs
were detected by flow cytometry on a FACScalibur. Cell
viability was determined by trypan blue and was 95%.
Effect of RSG on the Activation of OVA-Specific
Naı¨ve T Cells in a Primary Immune Response
Because the frequency of OVA-specific T cells is very low
in immunized animals, the primary activation of a naı¨ve T
cell is difficult to detect. To avoid this problem, a detect-
able number of naı¨ve T cells purified from DO11.10 mice
were adoptively transferred into BALB/c mice. Briefly,
LNs and spleen were collected from DO11.10 mice and
smashed. After red blood cell lysis, cells were labeled
with CFSE. Cells were enumerated and dead cells,
stained for trypan blue, were excluded. Cells (10  106)
were injected intravenously in the lateral tail vein of
BALB/c mice (day 2). On day 0, the mice received an
intratracheal injection of OVA-DC, RSG/OVA-DC, or con-
trol unpulsed DCs. On day 4, MLNs were collected, ho-
mogenized, and stained for the presence of KJ1-26
CD4 reactive OVA-specific T cells. Some of the LN cells
(200,000 cells/well in triplicates) were resuspended in
RPMI 1640 containing 5% fetal calf serum and antibiotics
and placed in 96-well plates. Four days later, superna-
tants were harvested and analyzed for the presence of
Th1 (IFN-) and Th2 (IL-4, IL-5, and IL-10) cytokines by
enzyme-linked immunosorbent assay (BD Pharmingen).
Effect of PPAR- Agonists on the Potential of
DCs to Prime for Eosinophilic Airway
Inflammation
On day 0, BALB/c mice were injected intratracheally with
unpulsed DCs, OVA-DCs treated or not with ciglitazone
(ciglitazone/OVA-DCs), or with RSG (RSG/OVA-DCs). To
confirm the specificity of the phenomenon, RSG/OVA-
DCs were also treated or not with the antagonist GW9662
(GW9662/RSG/OVA-DCs). In some experiments, mice re-
ceived 250 g of blocking anti-IL-10R antibodies or con-
trol antibodies (BD) 1 day before secondary challenge.
From days 10 to 13, mice were exposed to 30-minute
OVA aerosols (Grade III, Sigma). Mice were sacrificed 24
hours after the last aerosol. Bronchoalveolar lavage
(BAL) was performed with 3  1 ml of Ca2- and Mg2-
free HBSS (Invitrogen) supplemented with 0.1 mmol/L of
sodium ethylenediaminetetraacetic acid. The BAL fluid
was centrifuged; the cells were resuspended in HBSS,
and enumerated in a hemocytometer. After washing,
cells were stained for 30 minutes with anti-I-Ad/I-Ed FITC
(macrophages), anti-CCR3 PE (eosinophils), anti-CD3
cy-chrome, anti-B220 cy-chrome (T and B cells, respec-
tively), and anti-CD11c APC (macrophages) in PBS con-
taining 0.5% bovine serum albumin and 0.01% sodium
azide. Cells were washed and analyzed by flow cytom-
etry as previously described.37
Airway Histology
After BAL was performed, 1 ml of fixative was gently
infused through the catheter. The lungs were resected
and embedded in paraffin. Four-m sections were per-
formed and stained with May-Grunwald Giemsa.
Cytokine Measurements in MLNs in a
Secondary Response
MLNs were removed, homogenized, and resuspended in
RPMI 1640 containing 5% fetal calf serum and antibiotics
before enumeration. Ex vivo production of cytokines by T
cells collected from the MLNs was measured after restimu-
lation of 2  106 cells/ml with 10 g/ml of OVA for 4 days.
Statistical Analysis
For all experiments, the difference between the groups
was calculated using the Mann-Whitney U-test for un-
paired data. Differences were considered significant if P
was 0.05.
Results
We have previously established a model of adoptive
transfer of bone marrow-derived DCs (BM-DCs) pulsed
with OVA into the trachea of naı¨ve mice. This model
generates a primary OVA-specific immune response in
the lung draining MLNs33 that leads to Th2 priming. When
mice are challenged with OVA aerosols, a Th2-depen-
dent eosinophilic airway inflammation develops.32 This
model was used to test the effect of RSG.
RSG Impairs OVA-Induced BM-DCs Maturation
We have previously shown that mouse spleen DCs taken
from Flt-3L-treated mice express the PPAR-.21 By stain-
ing permeabilized DCs with a polyclonal rabbit anti-
PPAR- antibody, we confirmed that BM-DCs also ex-
press PPAR- (Figure 1). We next investigated whether
RSG, a PPAR- agonist, could alter the OVA-induced
maturation of BM-DCs. Compared to unpulsed DCs, the
expression of the co-stimulatory molecules CD40, CD80,
and CD86, but also of MHC II was increased in OVA-DCs
(100 g OVA/ml), a phenomenon probably caused by
trace amounts of LPS in commercially available OVA.
However, PPAR- activation by RSG treatment did not
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modify the expression of these markers on the cells (data
not shown). Compared to unpulsed DCs, OVA-DCs ex-
press a higher amount of CCR7, as assessed by
CCL19-Fc binding (Figure 2). However, compared to
untreated OVA-pulsed DCs, CCR7 expression was
down-regulated in cells treated with RSG. These data
suggest that PPAR- activation alters DC maturation by
affecting the expression of CCR7, a chemokine receptor
involved in DC emigration, but not the synthesis of co-
stimulatory molecules and MHC II.
Activation of PPAR- Inhibits the Migration of
OVA-DCs in Vivo
Because the treatment of OVA-pulsed DCs with RSG
decreased the expression of CCR7, we next hypothe-
sized that PPAR- activation might affect the migratory
capacities of DCs to the MLNs. As shown in Figure 3,
when injected into the trachea, CFSE-labeled OVA-DCs
could be detected in the MLNs 24 hours after the instil-
lation.32,37 However, the treatment of OVA-DCs with RSG
reduced their capacity to reach the MLNs, as compared
to mice injected with OVA-DCs. These data were con-
firmed in vitro in chemotaxis assays performed in tran-
swells, where the migration of OVA-DCs treated with RSG
at the dose of 10 mol/L in response to the CCR7 ligand
MIP-3 was highly reduced as compared to OVA-DCs.
Treatment of OVA-DCs with 1 mol/L of RSG did not
modify the migration as compared to untreated OVA-DCs
(data not shown). These data suggest that the activation
of PPAR- interferes with the CCR7-mediated migratory
capacities of DCs. Because only the dose of 10 mol/L of
RSG altered DC migration in vitro, all further experiments
were performed with this single dose of RSG.
Activation of PPAR- Affects T-Cell Proliferation
and Differentiation in the MLNs
As PPAR- activation affects the migration of OVA-pulsed
DCs to the MLNs, we next investigated whether it could
also impact the activation of naı¨ve T cell by DCs within the
MLNs. To this end, naı¨ve T cells from DO11.10 mice were
labeled with CFSE and adoptively transferred, on day2,
into BALB/c mice. On day 0, these mice received an
intratracheal administration of OVA-DCs, RSG/OVA-DCs,
or unpulsed DCs. Flow cytometry was used to track cell
division of CFSE-labeled T cells in MLNs. Figure 4 shows
that 4 days after transfer of OVA-DCs, some transgenic T
cells had already undergone seven divisions. In mice that
received RSG/OVA-DC, some T cells also reached the
Figure 1. PPAR- expression in BM-DCs. DCs were fixed, permeabilized,
and stained for PPAR- expression (black histogram). White histogram
represents fluorochrome-matched isotype control mAbs.
Figure 2. Effect of RSG treatment on CCR7 expression by DCs. BM-DCs were
pulsed or not overnight with 100 g/ml of OVA in the presence or in the
absence of 10 mol/L of RSG. LPS at the dose of 500 ng/ml was also used as
a positive control. Cells were incubated with CCL19-Fc for 30 minutes before
addition of PE-labeled anti-human IgG (black histograms). White histo-
gram represents fluorochrome-matched isotype control mAbs.
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seventh division peak, but the total number of naı¨ve T
cells activated and recruited into divisions was lower as
compared to the group immunized with OVA-DCs. As
expected, in mice immunized with unpulsed DCs, naı¨ve T
cells failed to divide (data not shown).
As PPAR- activation impacts the activation of OVA-
specific naı¨ve T cells in the MLNs, we next investigated
whether the cytokine profile of T cells obtained from the
MLNs was also changed. At day 4, cells from MLNs of
mice that received OVA-DC, RSG/OVA-DCs, or unpulsed
DCs were plated at 37°C for another 4-day period in the
absence of OVA. The supernatants were then collected
and assayed for the presence of IL-4, IL-5, IL-10, and
IFN-. As expected, in mice that received OVA-DCs, T
cells produced more IL-4, IL-5, IL-10, and IFN- than the
cells of mice that were injected with unpulsed DCs (Fig-
ure 5). However, when mice were instilled with RSG/OVA-
DCs, the production of IL-4, IL-5, and IFN- was identical
but the level of the immunoregulatory cytokine IL-10 was
dramatically enhanced (2.9-fold increase) as compared
to the mice immunized with OVA-DCs. These results
show that activation of PPAR- affects T-cell activation
and modifies the nature of the primary immune response
in the MLNs.
Activation of PPAR- Reduces Eosinophilic
Inflammation Induced by DCs
As PPAR- activation in DCs induced a T-cell response in
the MLNs with maintained levels of IL-4, IL-5, and IFN-,
but increased levels of IL-10, we next studied whether
PPAR- stimulation in DCs could modify their inherent
capacity to prime for eosinophilic airway inflammation on
secondary challenge to OVA aerosol. For this purpose,
mice were immunized as described before and re-ex-
posed to OVA aerosols 10 days later.32,37 BAL fluids
were collected 24 hours after the last OVA aerosol expo-
sure. As expected, in mice that received unpulsed DCs,
only a few inflammatory cells, mainly macrophages, were
observed in the BAL (Figure 6). In contrast, in mice
immunized with OVA-DCs, a strong cell recruitment oc-
curred as confirmed by the high number of lymphocytes
and eosinophils in the BAL fluid of these mice. However,
when mice received OVA-DCs treated with RSG (RSG/
OVA-DCs) or with ciglitazone, another PPAR- agonist
(ciglitazone/OVA-DCs), the number of inflammatory cells
including lymphocytes and eosinophils was significantly
reduced as compared to mice immunized with OVA-DCs.
To confirm the specificity of the phenomenon, in some
experiments, mice also received RSG/OVA-DCs pre-
treated with the PPAR- antagonist GW9662. In mice that
received GW9662-treated DCs, the eosinophilia was re-
stored and was comparable to the one present in mice
that received OVA-DCs. Because RSG-treated DCs in-
duced a T-cell response with high levels of IL-10, the
importance of this cytokine in the establishment of airway
eosinophilia was investigated. For this purpose, some
mice that received RSG/OVA-DCs on day 0 were injected
intraperitoneally with 250 g of blocking anti-IL-10R
antibodies 1 day before the first aerosol exposure. As
Figure 3. RSG treatment inhibits the migration of OVA-pulsed DCs. BM-DCs
were pulsed or not with OVA overnight in the presence or in the absence of
RSG (RSG/OVA-DCs). The next day, DCs were labeled with CFSE and 1 
106 OVA-DCs, RSG/OVA-DCs, or unpulsed DCs were instilled into the tra-
chea of naı¨ve BALB/c mice. Twenty-four hours later, the presence of migrat-
ing CFSE-labeled DCs was investigated in the MLNs. Top: Plots show one
representative mouse of four. The histogram represents the mean number of
CFSE DCs  SEM from five mice per group.
Figure 4. RSG impairs T-cell proliferation in the MLNs. On day 2, BALB/c
mice received a cohort of CFSE-labeled OVA-specific naı¨ve T cells. On day 0,
mice were administered intratracheally with OVA-DCs, RSG/OVA-DCs, or
with unpulsed DCs. Four days later, the proliferation of CD4 KJ1–26
CFSE T cells was analyzed by flow cytometry. Results show one represen-
tative experiment of 10 to 12 mice per group. *, P  0.05.
Figure 5. RSG-treated DCs modify the pattern of cytokine production of
naı¨ve T cells. On day 2, BALB/c mice received a cohort of CFSE-labeled
OVA-specific naı¨ve T cells. On day 0, mice were administered intratracheally
with OVA-DCs, RSG/OVA-DCs, or with unpulsed DCs. Four days later, T cells
from MLNs were collected and incubated for another 4-day period at 37°C.
Supernatants were harvested and assayed for the presence of IL-4, IL-5, IL-10,
and IFN-. Results are represented as mean  SEM from 10 to 12 mice per
group. *, P  0.05.
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shown in Figure 6, the pretreatment of mice with anti-IL-
10R could partially restore the BAL eosinophilia as com-
pared to mice injected with RSG/OVA-DCs, suggesting
that the effects induced by RSG-treated DCs were partly
mediated through an IL-10-dependent mechanism.
Because the activation of PPAR- reduced the number
of inflammatory cells in the BAL, we next looked at the
inflammation at the tissue level. Histological analysis of
the lungs of mice injected with OVA-DCs and re-exposed
to OVA aerosols revealed strong perivascular and peri-
bronchial inflammatory lesions (Figure 7) composed
mainly of eosinophils and mononuclear cells. These
changes were absent from the lungs of mice injected with
unpulsed DCs (data not shown).32 Interestingly, in the
lungs of mice injected with RSG/OVA-DCs, less inflam-
matory cells were present around the bronchi or around
the vessels of the lungs compared to mice immunized
with OVA-DCs.
Activation of PPAR- Impairs Cytokine
Production in MLNs
To study the mechanism of inhibition of eosinophilic air-
way inflammation, we quantified the production of cyto-
kines by T cells from MLNs. To this end, MLNs were
collected 24 hours after the last aerosol exposure, ho-
mogenized, and cells were restimulated in vitro for 4 days
with OVA. Supernatants were harvested and assayed for
the presence of Th1/Th2 cytokines. In mice that received
an intratracheal injection of OVA-pulsed DCs, the re-
stimulation of MLNs with OVA led to a strong Th2 re-
sponse with an up-regulation of the production of IL-4
and IL-5, as compared to control mice that received
unpulsed DCs (Figure 8). Interestingly, in mice injected
with RSG/OVA-DCs, the levels of IL-4 and IL-5 produced
by MLN T cells were similar to those observed in the
OVA-DC group. However, the levels of IL-10 but also of
IFN- were higher in mice injected with RSG/OVA-DCs
than in mice that received OVA-DCs.
Discussion
Migration of DCs from the periphery to the draining LN is
a critical step for the induction of immunity. However, the
signals controlling the migration of DCs to the nodes and
controlling immunity are still poorly understood. Recently
the role of lipid mediators such as polyunsaturated fatty
acids, leukotrienes, and prostaglandins has received a
lot of attention as inflammatory mediators with immuno-
modulatory potential on DCs and T-cell activation. Many
of these lipid mediators such as the -linoleic acid, -li-
noleic acid, arachidonic acid, 9-hydroxyoctadeca-9Z,
11E-dienoci acid (9-HODE), 15d-PGJ2 are agonists of
PPAR-, a nuclear receptor widely expressed on cells of
the immune system, including DCs. Here we show that
PPAR- activation by a selective agonist, namely RSG,
impairs the emigration of intratracheally injected BM-DCs
from the lung to the MLNs, probably by reducing the
expression of the CCR7 receptor necessary for migration
to the draining nodes. In addition, RSG-treated DCs
failed to respond to the CCR7 ligands CCL19 and CCL21
in a chemotaxis assay performed in vitro (data not
shown). PPAR- activation has also been reported to
affect human DC maturation by reducing different co-
stimulatory molecules,22,38 although in our hands, no ef-
fect on the expression of CD40, CD80, or CD86 was
observed (data not shown). Differences in the mode of
stimulation or in the origin of DCs might explain this
discrepancy.21
In the next step, we then investigated whether the
intratracheal injection of OVA-DCs treated with RSG
could affect the proliferation of adoptively transferred
naive OVA-specific T cells. In mice injected with RSG/
OVA-DCs, the number of cell divisions was not affected
but the number of OVA-specific T cells recruited into
divisions was decreased as compared to mice instilled
with OVA-DCs. Therefore, treatment of DCs with RSG
does not alter the antigen capture capability nor the
capacity to activate naı¨ve T cells, but merely reduces the
strength of the induced T-cell response. The lower ex-
pression of CCR7 on DCs treated with RSG might limit the
number of antigen-presenting cells reaching the thoracic
nodes, which might, in turn, affect the outcome of the
primary immune response as already reported in plt
mice39 or CCR7-deficient mice.40 Interestingly, the pat-
tern of cytokines produced by the T cells activated by
RSG/OVA-DCs was different from the one induced by
OVA-DCs. As compared to mice injected with OVA-DC,
the production of the immunoregulatory cytokine IL-10
was dramatically increased in mice that received RSG/
OVA-DCs, whereas the levels of IL-4, IL-5, and IFN-
were similar in both groups. These results are in discrep-
ancy with another study in which we showed that RSG
induced a general decrease in the cytokine production
induced by FITC-OVA.26 In the latter study, RSG was
Figure 6. RSG-treated DCs modify the cellular composition of BAL. On day
0, mice received an intratracheal injection of OVA-DCs, ciglitazone/OVA-
DCs, RSG/OVA-DCs treated with the PPAR- antagonist GW9662 (GW9662/
RSG/OVA-DCs), or unpulsed DCs. From days 10 to 13, mice were exposed
to OVA aerosols. To test the role of IL-10 in RSG-induced effects, some mice
that received RSG/OVA-DCs on day 0 were injected with anti-IL-10R (IL-
10Ra/RSG/OVA-DCs) 24 hours before aerosol exposure. Twenty-four hours
after the last aerosol, BAL was performed. Results are expressed as mean 
SEM from 8 to 10 mice per group. *, P  0.05.
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introduced directly into the trachea of mice and therefore
one cannot rule out an indirect effect of RSG on airway
DCs. Here, RSG was given in vitro to DCs and washed
away before instillation. The effects induced might strictly
be because of direct modifications of DC functions by
PPAR- agonists. We have previously shown that OVA-
pulsed BM-DCs injected into the trachea lead to Th2
immunity that primes for the development of eosinophilic
airway inflammation on rechallenge with OVA aero-
sols.32,37 When the mice were instilled with RSG/OVA-
DCs and exposed to OVA aerosols 10 days later, T cells
from the LN restimulated in vitro with OVA produced the
same amounts of IL-4 and IL-5 but higher levels of IL-10
but also of IFN- as compared to mice that received
untreated OVA-DCs. In mice that received RSG-treated
DCs, the number of eosinophils in the BAL and lung
inflammation was dramatically reduced as compared to
mice injected with OVA-DCs. As the levels of IL-5 during
the secondary immune response are not affected by the
treatment of DCs with RSG, we can hypothesize that the
decreased eosinophilia might be because of the high
levels of IL-10 produced in these mice. IL-10 by acceler-
ating the eosinophil death41 may play an important reg-
ulatory role in airway allergic responses as already re-
ported.42,43 Our data suggest that RSG-treated DCs can
induce the generation of a population of IL-10- and IFN-
-producing T cells that could suppress some of the
features of asthma. These T cells have similarities with
Tr1 cells that also secrete high levels of IL-10 and IFN-
.44 More recently, it was shown that such regulatory T
cells could also inhibit Th2-specific responses in
vivo.45,46 However, further experiments aimed at charac-
Figure 7. RSG-treated DCs reduce the pulmonary inflammatory response in the lung. On day 0, mice received an intratracheal injection of OVA-DCs,
RSG/OVA-DCs, or unpulsed DCs. From days 10 to 13, mice were exposed to OVA aerosols. Four-m sections of the lungs were stained with May-Grunwald
Giemsa. Mice that received OVA-DCs revealed strong perivascular and peribronchial inflammatory lesions composed mainly of eosinophils and mononuclear
cells. These features were strongly reduced in the lungs of mice injected with RSG/OVA-DCs. Original magnifications: 20 (A, C); 100 (B, D).
Figure 8. RSG-treated DCs modify the pattern of cytokine production of T
cells after re-exposure of the mice to OVA aerosols. On day 0, mice received
an intratracheal injection of OVA-DCs, RSG/OVA-DCs, or unpulsed DCs.
From days 10 to 13, mice were exposed to OVA aerosols. Twenty-four hours
after the last aerosol, cells from MLNs were collected and restimulated for 4
days in the presence of OVA. The supernatants were harvested and assayed
for the presence of IL-5, IL-10, and IFN-. Results show the mean SEM from
8 to 10 mice per group. *, P  0.05.
PPAR- Reduces Airway Eosinophilia in Asthma 269
AJP January 2004, Vol. 164, No. 1
terizing phenotypically and functionally the T cells in
MLNs of mice injected with RSG/OVA-DCs remain to be
performed. The production of IL-10 induced by RSG-
treated DCs was physiologically relevant as inhibition of
signaling through IL-10R with blocking antibodies par-
tially restored inflammation. Thus, from our data, it seems
that RSG-treated DCs can improve the features of asthma
when given during the sensitization phase. To test the
effect of RSG on an ongoing Th2 response, some mice
were injected with OVA-DCs and fed or not with RSG 30
minutes before each OVA aerosol. RSG failed to reduce
eosinophilic airway inflammation but inhibited lympho-
cytic and neutrophilic inflammation (data not shown).
These results are in contradiction with those from Trifilieff
and colleagues31 in which they show that another
PPAR- agonist (GI262570) could down-regulate eosin-
ophilic airway inflammation. The reasons of such differ-
ences between our results might be because of the route
of administration of each compound (gavage versus in-
tranasally).
It remains to be proven whether endogenous activa-
tors of PPAR- such as polyunsaturated fatty acids, ei-
cosanoids, and cyclopentenone prostaglandins (PGs)
contribute to down-regulation of sensitization to inhaled
allergens. Alveolar macrophages have been shown to
suppress the activation of T cells in the lung through
inhibitory effects on airway and interstitial DCs, mediated
by nitric oxide, transforming growth factor-, IL-10, or
IL-1RA.47 Alveolar macrophages are a rich source of
15d-PGJ2, a major PGD2 metabolite, which could down-
regulate DC function under steady-state conditions
through PPAR- activation. Similarly, at the resolution of
inflammation, there is high-level expression of the induc-
ible COX-2 enzyme, generating mainly PGD2 rather than
PGE2.
48 It is likely that metabolism of PGD2 would sub-
sequently dampen the immune response by ligation of
PPAR- in DCs. Finally, there is an association between
altered levels of plasma polyunsaturated fatty acids and
the risk to develop atopy, although it remains to be
proven that PPAR- stimulation of DCs would be impli-
cated as a mechanism to reduce sensitization to inhaled
allergens.49 The immunomodulatory capacity of PPAR-
agonists to inhibit sensitization to inhaled allergens
clearly deserves more attention.
This is another example of the extraordinary capacity
of PPAR- agonists to serve as anti-inflammatory com-
pounds.25,27–29 It was previous hypothesized that
PPAR- agonists might be good tools for therapeutic
intervention in asthma, because of their inhibiting effects
on chemokine release by bronchial epithelial cells.50 Our
data suggest that they have additional suppressing ef-
fects on airway DCs, known to be important in sensitiza-
tion to inhaled antigen and for maintaining established
eosinophilic airway inflammation.51
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